tbuckley/cabot-search huggingface dataset:
Multimodal lung cancer theranostics via manganese phosphate/quercetin particle
Authors: Chong Qiu, Fei Xia, Qingchao Tu, Huan Tang, Yinan Liu, Hongda Liu, Chen Wang, HaiLu Yao, Linying Zhong, Yuanfeng Fu, Pengbo Guo, Weiqi Chen, Xinyu Zhou, Li Zou, Licheng Gan, Jiawei Yan, Yichong Hou, Junzhe Zhang, Huanhuan Pang, Yuqing Meng, Qiaoli Shi, Guang Han, Xijun Wang, Jigang Wang
Journal: Molecular Cancer (2025)

The diagnosis and treatment of non-small cell lung cancer in clinical settings face serious challenges, particularly due to the lack of integration between the two processes, which limit real-time adjustments in treatment plans based on the patient's condition and drive-up treatment costs. Here, we present a multifunctional pH-sensitive core-shell nanoparticle containing quercetin (QCT), termed AHA@MnP/QCT NPs, designed for the simultaneous diagnosis and treatment of non-small cell lung cancer. Mechanistic studies indicated that QCT and Mn2+ exhibited excellent peroxidase-like (POD-like) activity, catalysing the conversion of endogenous hydrogen peroxide into highly toxic hydroxyl radicals through a Fenton-like reaction, depleting glutathione (GSH), promoting reactive oxygen species (ROS) generation in mitochondria and endoplasmic reticulum, and inducing ferroptosis. Additionally, Mn2+ could activate the cGAS-STING signalling pathway and promote the maturation of dendritic cells and infiltration of activated T cells, thus inducing tumor immunogenic cell death (ICD). Furthermore, it exhibited effective T2-weighted MRI enhancement for tumor imaging, making them valuable for clinical diagnosis. In vitro and in vivo experiments demonstrated that AHA@MnP/QCT NPs enabled non-invasive imaging and tumor treatment, which presented a one-stone-for-two-birds strategy for combining tumor diagnosis and treatment, with broad potential for clinical application in non-small cell lung cancer therapy.
Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Authors: Dieter Haffner, Francesco Emma, Lothar Seefried, Wolfgang Högler, Kassim M. Javaid, Detlef Bockenhauer, Justine Bacchetta, Deborah Eastwood, Martin Biosse Duplan, Dirk Schnabel, Philippe Wicart, Gema Ariceta, Elena Levtchenko, Pol Harvengt, Martha Kirchhoff, Oliver Gardiner, Federico Di Rocco, Catherine Chaussain, Maria Luisa Brandi, Lars Savendahl, Karine Briot, Peter Kamenický, Lars Rejnmark, Agnès Linglart
Journal: Nature Reviews Nephrology (2025)
A Response to Letter to the Editor: “Refining Risk Stratification for Locoregional Relapse in Clinical Stage IA Small-Sized Peripheral NSCLC After Segmentectomy”
Authors: Kazuo Nakagawa, Shun-Ichi Watanabe, Masashi Wakabayashi, Yuta Sekino
Journal: Journal of Thoracic Oncology (2025)
Quantifying cell divisions along evolutionary lineages in cancer
Authors: Martin Blohmer, David M. Cheek, Wei-Ting Hung, Maria Kessler, Foivos Chatzidimitriou, Jiahe Wang, William Hung, I-Hsiu Lee, Alexander N. Gorelick, Emma CE Wassenaar, Ching-Yeuh Yang, Yi-Chen Yeh, Hsiang-Ling Ho, Dorothee Speiser, Maria M. Karsten, Michael Lanuti, Sara I. Pai, Onno Kranenburg, Jochen K. Lennerz, Teh-Ying Chou, Matthias Kloor, Kamila Naxerova
Journal: Nature Genetics (2025)
Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammation
Authors: Stanislav Dikiy, Aazam P. Ghelani, Andrew G. Levine, Stephen Martis, Paolo Giovanelli, Zhong-Min Wang, Giorgi Beroshvili, Yuri Pritykin, Chirag Krishna, Xiao Huang, Ariella Glasner, Benjamin D. Greenbaum, Christina S. Leslie, Alexander Y. Rudensky
Journal: Nature Immunology (2025)

Abstract Regulatory T (T reg ) cells are a specialized CD4 + T cell lineage with essential anti-inflammatory functions. Analysis of T reg cell adaptations to non-lymphoid tissues that enable their specialized immunosuppressive and tissue-supportive functions raises questions about the underlying mechanisms of these adaptations and whether they represent stable differentiation or reversible activation states. Here, we characterize distinct colonic effector T reg cell transcriptional programs. Attenuated T cell receptor (TCR) signaling and acquisition of substantial TCR-independent functionality seems to facilitate the terminal differentiation of a population of colonic effector T reg cells that are distinguished by stable expression of the immunomodulatory cytokine IL-10. Functional studies show that this subset of effector T reg cells, but not their expression of IL-10, is indispensable for colonic health. These findings identify core features of the terminal differentiation of effector T reg cells in non-lymphoid tissues and their function.
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
Authors: Jiacheng He, Xiaolei Chai, Qiansen Zhang, Yang Wang, Yijie Wang, Xinyu Yang, Jingbo Wu, Bo Feng, Jing Sun, Weiwei Rui, Shuyin Ze, Yuanyuan Fu, Yumiao Zhao, Ying Zhang, Yao Zhang, Meizhen Liu, Chuang Liu, Meifu She, Xiangfei Hu, Xueyun Ma, Huaiyu Yang, Dawei Li, Senlin Zhao, Guichao Li, Zhen Zhang, Zhonghui Tian, Yanlin Ma, Lingyan Cao, Bo Yi, Dali Li, Ruth Nussinov, Charis Eng, Timothy A. Chan, Eytan Ruppin, J. Silvio Gutkind, Feixiong Cheng, Mingyao Liu, Weiqiang Lu
Journal: Nature Immunology (2025)
Photothermal‐Driven α‐Amylase‐Modified Polydopamine Pot‐Like Nanomotors for Enhancing Penetration and Elimination of Drug‐Resistant Biofilms
Authors: Xiangxiang Zhai, Yi Liu, Xiaomeng Hao, Ming Luo, Zhixue Gao, Jinmei Wu, Zili Yang, Ying Gan, Suling Zhao, Zhiyong Song, Jianguo Guan
Journal: Advanced Healthcare Materials (2025)

Abstract Biological enzyme‐functionalized antibacterial nanoparticles, which can degrade biofilm and kill bacteria under mild reaction conditions, have attracted much attention for the elimination of deep‐seated bacterial infections. However, the poor diffusion and penetration capabilities of recently developed biological enzyme‐functionalized antibacterial nanoparticles in biofilm severely impair the eradication efficacy of deep‐seated bacteria. Herein, a photothermal‐driven nanomotor (denoted as APPNM) is developed for enhancing the elimination of drug‐resistant biofilms and the eradication of deep‐seated bacteria. The nanomotor contained a pot‐like polydopamine (PDA) nanostructure and its outer surface is chemically immobilized with a layer of α‐amylases. Under exposure to 808 nm near‐infrared (NIR) laser irradiation, the self‐propelled nanomotors, integrating the α‐amylases to destroy the compact structure of biofilms, can penetrate deeply into biofilms and effectively eliminate them. Subsequently, they can accumulate on the surface of bacteria using the inherent bio‐adhesion property of PDA, thereby completely eradicating deep‐seated bacteria by photothermal effect. These synergistic effects enable them to exhibit superior antibiofilm effects and produce remarkable therapeutic efficacy with accelerated wound healing in vivo. With excellent biocompatibility, the as‐developed nanomotors have great potential to be applied for treating biofilm‐related infections.
2025 Clinical Trials Update on Hemophilia, <scp>VWD</scp>, and Rare Inherited Bleeding Disorders
Authors: Debbie Jiang, Michael Wang, Allison P. Wheeler, Stacy E. Croteau
Journal: American Journal of Hematology (2025)

ABSTRACT Clinical trial programs for inherited bleeding disorders feature an array of innovative prophylaxis options: engineered clotting factor concentrates, FVIIIa mimetics, gene therapies, and biologics to bolster thrombin generation (rebalancing agents). Increasingly, non‐hemophilia bleeding disorders and a broader demographic (females, children, and infants) are being incorporated into study populations. Ongoing clinical trials broadly address three themes: (1) indication expansion for licensed therapeutics in previously uninvestigated patient subgroups or clinical scenarios, (2) evaluation of efficacy and safety among other bleeding disorders such as von Willebrand disease, platelet function defects, and rare clotting factor deficiencies, and (3) longitudinal assessment of approved treatments particularly with regard to longer‐term efficacy outcomes such as musculoskeletal health and treatment‐specific safety outcomes including thrombotic risk and liver health. With these new prophylaxis modalities, providers must have a nuanced understanding of each therapy's mechanism of action, advantages, side effect profile, therapeutic limitations, and impact on hemostasis and laboratory monitoring. Treatment is no longer “one size fits all.” Rather, management is tailored to individual needs and preferences. Here, we review active investigational trials and highlight promising approaches in preclinical development, expanding the innovative, complex landscape of inherited bleeding disorders therapeutics.
Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth
Authors: Graziella Ribeiro de Sousa, Annaliese J Calzadilla, Enrique Grimaldo, Andrew M Donson, Lays Martin Sobral, Kendra M Jones, Tian Liu, Vladimir Amani, Sujatha Venkataraman, Nathan A Dahl, Jean M Mulcahy Levy, Tzu Phang, Rajeev Vibhakar, Todd Hankinson, Michael Handler, Elvis Terci Valera, Nicholas K Foreman, Andrea M Griesinger
Journal: Neuro-Oncology (2025)

Posterior fossa molecular subtype A (PFA) ependymoma occurs in young children and is the deadliest subtype of pediatric ependymoma. High-risk subtypes with chromosome 1q+ and/or 6q- exhibit significantly poorer outcome compared to wild-type PFA. However, 50% of wild-type PFA patients relapse and there is a high risk of gaining chromosome 1q at recurrence. We previously found constitutively active NF-κB, through loss of LDOC1, led to chronic IL-6 secretion and an overall immunosuppressive tumor microenvironment in the higher risk wild-type PFA ependymoma subset (PFA1). In this study, we delineate the mechanistic consequences of LDOC1 loss in PFA1, using our PFA ependymoma in vitro and in vivo models under normoxia and hypoxia conditions. We noted chromatin compaction by H3K27me3 at the LDOC1 loci results in loss of LDOC1 gene expression. Restoration of LDOC1 was sufficient to reduce proliferation, NF-κB signaling and significant decrease in IL-6 secretion. Furthermore, tumors implanted with LDOC1- transduced cells in vivo were out competed by non-transduced cells, suggesting loss of LDOC1 is required for PFA tumor growth. These findings shed further light on the biology of PFA1 ependymoma and the role LDOC1 loss has on the tumor and immunobiology of high risk pediatric ependymoma.
Efficacy and Cellular Mechanism of Biomimetic Marine Adhesive Protein‐Based Coating Against Skin Photoaging
Authors: Bo Xue
Journal: Advanced Healthcare Materials (2025)

Abstract Skin photoaging is a problem worldwide, clinically often accompanied by collagen decline, increased wrinkles, loss of skin elasticity, structurally weakened skin, and other complications, which urgently demand effective treatment strategies. The biosafety and efficacy of single‐function therapies for repairing skin photoaging are still challenging for clinical medicine today. At present, numerous studies report that the wet adhesive proteins driven from marine organisms play a critical role in the biomedical material field, particularly in aquatic environments. In this study, a natural recombinant protein‐based coating from scallop byssal protein is prepared to investigate the efficacy and cellular mechanism in accelerating the repair of UVB‐induced photoaging in a mouse model. In vitro experiments demonstrate the safety of the coating and its efficacy in enhancing cell adhesion, spreading, proliferation, and migration. Additionally, the coating effectively scavenges reactive oxygen species, promotes the expression of cell adhesion molecules and anti‐apoptotic proteins, and inhibits inflammatory responses. In animal tests, the coating exhibited remarkable adsorption properties, showing significant potential for in situ regenerative therapy, as evidenced by its ability to protect against UVB‐induced skin photoaging and oxidative stress. These findings suggest that Sbp9 Δ coating provides a simple, safe, and innovative strategy for treating skin photoaging.
Next‐Generation Oral Ulcer Management: Integrating Cold Atmospheric Plasma (CAP) with Nanogel‐Based Pharmaceuticals for Inflammation Regulation
Authors: Yanfen Zheng, Ziqi Zhuang, Renwu Zhou, Luo Zheng, Changhong Li, Rusen Zhou, Yuting Gao, Liang Zhang, Yating Zheng, Liqian Zhao, Syed Faheem Askari Rizvi, Bocheng Yang, Lili Jiang, Jinyong Lin, Anqi Wang, Wei Zhou, Hongwei Cheng, Dong Li, Chengchao Chu, Erik W. Thompson, Yunlong Wu, Gang Liu, Yun Zeng, Peiyu Wang
Journal: Advanced Healthcare Materials (2025)

Oral ulcers, affecting 27.9% of adults, can lead to malnutrition and dehydration, especially in individuals with diabetes, cancer, viral infections, and autoimmune diseases. Existing treatments-including oral films, sprays, frosts, and powders-often fail to be effective due to rapid dilution and clearance in the moist oral environment. This study is the first to investigate the use of Cold Atmospheric Plasma (CAP) for treating oral ulcers and its underlying molecular mechanisms. A novel high-bioavailability, mucoadhesive therapy combining handheld three dimensions (3D) multi-microhole CAP is developed with a nanogel-based pharmaceutical system containing glucose oxidase (GOx) and catalase (CAT), termed GCN. These results showed that both CAP alone and CAP combined with GCN significantly accelerate oral ulcer healing, modulate immune responses, and activate the Epidermal Growth Factor Receptor (EGFR) in acetic acid-induced oral ulcers, outperforming untreated controls and the conventional medication, Watermelon Frost (WF). Furthermore, the CAP+GCN combination enhances therapeutic effects by promoting fibroblast generation. CAP pretreatment also enhances cell permeability and nanoparticle uptake, improving tissue adhesion. These findings are validated in primary Human Gingival Fibroblasts (HGF) and Human Periodontal Ligament Stem Cells (PDLSC) from healthy donors, as well as an oral ulcer model in rats, demonstrating superior biocompatibility and safety.
Enhanced Antigen Capture via Cholinephosphate‐Mediated Cell Membrane Interactions to Improve In Situ Tumor Vaccines
Authors: Ting Song, Xin Cui, Jiansheng Lin, Zonghua Liu, Linghong Huang, Wei Xue
Journal: Advanced Healthcare Materials (2025)

Inadequate antigen capture and insufficient antigen-presenting cell (APC) activity at tumor sites limit the effectiveness of in situ vaccines. To address this, poly(glutamic acid-cholinephosphate) (pGluCP) is introduced as a polymer with cell membrane adhesion properties capable of capturing both water-soluble and insoluble membrane antigens from necrotic tumor cells while recruiting more APCs. The approach uses manganese-mineralized black phosphorus (MnBP) coated with pGluCP and αPD-1 antibodies to create the MnBP@pGluCP-αPD-1 complex for in situ vaccines. MnBP eradicates tumor cells via photothermal effects, releasing antigens, while Mn2⁺ ions activate the intracellular STING pathway, acting as an adjuvant. pGluCP captures these antigens, forming pathogen-mimicking micro-nanoparticles, leading to an in situ vaccine (MnBP@pGluCP/antigens) that co-localizes antigens and adjuvants. The αPD-1 antibody alleviates tumor-induced immune suppression, enhancing tumor cell-specific killing. This study demonstrates the potential of leveraging cholinephosphate-cell membrane interactions to improve antigen presentation efficiency, significantly bolstering the efficacy of in situ tumor vaccines and opening new avenues for advanced cancer immunotherapy.
Glycoengineered Stem Cell-Derived Extracellular Vesicles for Targeted Therapy of Acute Kidney Injury
Authors: So Hee Kim, Chan Ho Kim, Chang Hyun Lee, Jungmi Lee, Heegun Kang, Sohyun Cho, Won Ho Jang, Minsung Park, Minji Ha, Jiyeon Kim, Wooram Um, Seunglee Kwon, Sangho Lee, Jin Woong Kim, Chan-Hwa Chung, Jae Hyung Park
Journal: Biomaterials (2025)
Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries
Authors: Alan Rosales, Leo O. Blondel, Joshua Hull, Qimeng Gao, Nihal Aykun, Jennifer L. Peek, Alejandra Vargas, Sophia Fergione, Mingqing Song, Matthew H. Wilson, Andrew S. Barbas, Aravind Asokan
Journal: Nature Biomedical Engineering (2025)
Genome assembly of a living fossil, the Atlantic horseshoe crab <i>Limulus polyphemus</i>, reveals lineage-specific whole genome duplications, transposable element-based centromeres and a ZW sex chromosome system
Authors: Kate R Castellano, Michelle L Neitzey, Andrew Starovoitov, Gabriel A Barrett, Noah M Reid, Vidya S Vuruputoor, Cynthia N Webster, Jessica M Storer, Nicole R Pauloski, Natalie J Ameral, Susan L McEvoy, M Conor McManus, Jonathan B Puritz, Jill L Wegrzyn, Rachel J O’Neill
Journal: Molecular Biology and Evolution (2025)

Abstract Horseshoe crabs, considered living fossils with a stable morphotype spanning ∼445 million years, are evolutionarily, ecologically and biomedically important species experiencing rapid population decline. Of the four extant species of horseshoe crabs, the Atlantic horseshoe crab, Limulus polyphemus, has become an essential component of the modern medicine toolkit. Here, we present the first chromosome-level genome assembly, and most contiguous and complete assembly to date, for Limulus polyphemus using nanopore long-read sequencing and chromatin conformation analysis. We find support for three horseshoe crab-specific whole genome duplications, but none shared with Arachnopulmonata (spiders and scorpions). Moreover, we discovered tandem duplicates of endotoxin-detection pathway components Factor C and Factor G, identify candidate centromeres consisting of Gypsy retroelements, and classify the ZW sex chromosome system for this species and a sister taxon, Carcinoscorpius rotundicauda. Finally, we revealed this species has been experiencing a steep population decline over the last 5 million years, highlighting the need for international conservation interventions and fisheries-based management for this critical species.
Sex-specific and cell-type-specific changes in chaperone-mediated autophagy across tissues during aging
Authors: Rabia R. Khawaja, Adrián Martín-Segura, Olaya Santiago-Fernández, Rebecca Sereda, Kristen Lindenau, Mericka McCabe, Adrián Macho-González, Maryam Jafari, Aurora Scrivo, Raquel Gomez-Sintes, Bhakti Chavda, Ana Rosa Saez-Ibanez, Inmaculada Tasset, Esperanza Arias, Xianhong Xie, Mimi Kim, Susmita Kaushik, Ana Maria Cuervo
Journal: Nature Aging (2025)

Aging leads to progressive decline in organ and tissue integrity and function, partly due to loss of proteostasis and autophagy malfunctioning. A decrease with age in chaperone-mediated autophagy (CMA), a selective type of lysosomal degradation, has been reported in various organs and cells from rodents and humans. Disruption of CMA recapitulates features of aging, whereas activating CMA in mice protects against age-related diseases such as Alzheimer's, retinal degeneration and/or atherosclerosis. However, sex-specific and cell-type-specific differences in CMA with aging remain unexplored. Here, using CMA reporter mice and single-cell transcriptomic data, we report that most organs and cell types show CMA decline with age, with males exhibiting a greater decline with aging. Reduced CMA is often associated with fewer lysosomes competent for CMA. Transcriptional downregulation of CMA genes may further contribute to CMA decline, especially in males. These findings suggest that CMA differences may influence organ vulnerability to age-related degeneration. Using single-cell imaging of a fluorescent chaperone-mediated autophagy (CMA) reporter and RNA sequencing data, the authors present a resource on basal CMA activity across organs, cell types and sexes in young and old mice, offering a comprehensive overview of changes in this proteostatic mechanism in the context of aging.
Subcutaneous depth-selective spectral imaging with mμSORS enables noninvasive glucose monitoring
Authors: Yifei Zhang, Lili Zhang, Long Wang, Shuai Shao, Bei Tao, Chunrui Hu, Yufei Chen, Yue Shen, Xianbiao Zhang, Shijia Pan, Hua Cao, Ming Sun, Jia Shi, Chunhong Jiang, Minghui Chen, Lin Zhou, Guang Ning, Chang Chen, Weiqing Wang
Journal: Nature Metabolism (2025)
Multi-omic profiling of sarcopenia identifies disrupted branched-chain amino acid catabolism as a causal mechanism and therapeutic target
Authors: Xinrong Zuo, Rui Zhao, Minming Wu, Yanyan Wang, Shisheng Wang, Kuo Tang, Yang Wang, Jie Chen, Xiaoxiang Yan, Yang Cao, Tao Li
Journal: Nature Aging (2025)
GPT-4 assistance for improvement of physician performance on patient care tasks: a randomized controlled trial
Authors: Ethan Goh, Robert J. Gallo, Eric Strong, Yingjie Weng, Hannah Kerman, Jason A. Freed, Joséphine A. Cool, Zahir Kanjee, Kathleen P. Lane, Andrew S. Parsons, Neera Ahuja, Eric Horvitz, Daniel Yang, Arnold Milstein, Andrew P. J. Olson, Jason Hom, Jonathan H. Chen, Adam Rodman
Journal: Nature Medicine (2025)
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
Authors: Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep M. Martí, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Tahamtan Ahmadi, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Sonja Zweegman
Journal: Nature Medicine (2025)

Abstract Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing. Major secondary endpoints included complete response (CR) or better (≥CR) rate, progression-free survival and sustained MRD-negativity rate at 10 − 5 . At a median follow-up of 58.7 months, the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P &lt; 0.0001). Rates of ≥CR (81.2% versus 61.6%; P &lt; 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P &lt; 0.0001) were significantly higher with D-VRd versus VRd. Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41–0.79; P = 0.0005). Adverse events were consistent with the known safety profiles for daratumumab and VRd. Combining daratumumab with VRd produced deeper and more durable MRD responses versus VRd alone. The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM. ClinicalTrials.gov registration: NCT03652064 .
Endobronchial ultrasound-guided cryobiopsy of a rare epicardial tumour
Authors: Toshiyuki Nakai, Atsushi Miyamoto, Mana Ogawa, Akimasa Morisaki, Nobuhiro Izumi, Sayaka Tanaka
Journal: Pulmonology (2025)

Background Cardiac tumors are rare, and a nonsurgical diagnosis is preferred for determining appropriate treatment strategies.